Adagrasib with cetuximab for treating KRAS G12C mutation-positive advanced colorectal cancer after 1 treatment line [TSID12305]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (TA307)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 March 2014
Atezolizumab with chemotherapy for adjuvant treatment of stage 3 colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID6646]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 1 January 2012Published: 24 January 2007
Bevacizumab (Avastin and biosimilars) with fluoropyrimidine-based chemotherapy for untreated metastatic colorectal cancer [ID6465]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: 25 February 2026
Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (TA212)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 December 2010
Capecitabine and oxaliplatin in the adjuvant treatment of stage 3 (Dukes' C) colon cancer (TA100)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 April 2006
Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 30 September 2026
Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 25 September 2017Published: 29 March 2017
Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (TA242)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 January 2012
Colon cancer (adjuvant) - irinotecan [ID379]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer (TA668)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 6 January 2021
Entrectinib for treating NTRK fusion-positive solid tumours in people 12 years and over (terminated appraisal) (TA1118)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 January 2026
Entrectinib for treating NTRK fusion-positive solid tumours in people 1 month to 11 years [TSID12116]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Fruquintinib for previously treated metastatic colorectal cancer (TA1079)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 July 2025
Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer (TA61)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 May 2003
High resolution anoscopy and laser therapy for intraepithelial neoplasia of the anus in high risk or immunocompromised patientsStatus:Topic prioritisationProgramme:Interventional procedures guidanceExpected publication date: TBC
Laparoscopic surgery for colorectal cancer (TA105)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 August 2006
Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: 21 May 2026
Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 May 2020
Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA1065)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 May 2025
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA716)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 July 2021
Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal) (TA240)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 29 March 2017Published: 14 December 2011
Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency (TA914)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 September 2023
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA709)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 June 2021
Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) (TA334)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 February 2015
Regorafenib for previously treated metastatic colorectal cancer (TA866)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 February 2023
Repotrectinib for treating NTRK fusion-positive advanced solid tumours in people 12 years and over [TSID12147]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy ID6482 [ID6482]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Selective internal radiation therapy for unresectable colorectal metastases in the liverStatus:Topic prioritisationProgramme:Interventional procedures guidanceExpected publication date: TBC
Signatera molecular residual disease assay (MT741)Status:Topic prioritisationProgramme:Medical technologies guidanceExpected publication date: TBC
The Extraperitoneal approach to left sided colorectal resections ( EXPERTS) ProcedureStatus:Topic prioritisationProgramme:Interventional procedures guidanceExpected publication date: TBC
Trifluridine–tipiracil for previously treated metastatic colorectal cancer (TA405)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 August 2016
Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments (TA1008)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 September 2024
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC